Processa Pharmaceuticals (PCSA) Shares Outstanding (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Shares Outstanding (Entity) came in at $2.7 million in Q1 2026, up 602.71% YoY from $381072.0 in Q1 2025, and up 104.53% on a QoQ basis from $1.3 million in Q4 2025.
Processa Pharmaceuticals (PCSA) Shares Outstanding (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 15 years of Shares Outstanding (Entity) data on file, last reported at $2.7 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 602.71% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (up 602.71% YoY) and the FY2025 annual result came in at $1.3 million, up 969.7% from the prior year.
- Shares Outstanding (Entity) rose to $2.7 million in Q1 2026, from $1.3 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $2.7 million in Q1 2026 to a low of $31839.0 in Q2 2022.
- A 5-year average of $465643.5 and a median of $114439.0 in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) climbed 2.02% — and 2025, when it jumped 1515.79%.
- Tracing PCSA's Shares Outstanding (Entity) over 5 years: stood at $32271.0 in 2022, then jumped by 60.02% to $51640.0 in 2023, then jumped by 137.02% to $122396.0 in 2024, then soared by 969.7% to $1.3 million in 2025, then jumped by 104.53% to $2.7 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $2.7 million (Q1 2026), $1.3 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.09 Bn | 131.23 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.66 Bn | 77.66 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.86 Bn | 59.67 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.87 Bn | 36.77 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.45 Bn | 28.15 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 445.06 Mn |
| 10 | Processa Pharmaceuticals | 5.69 Mn | 5.69 Mn | - | 2.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.62 Mn |
| Dec 31, 2025 | 1.31 Mn |
| Sep 30, 2025 | 1.90 Mn |
| Jun 30, 2025 | 622,772.00 |
| Mar 31, 2025 | 381,072.00 |
| Dec 31, 2024 | 122,396.00 |
| Sep 30, 2024 | 131,040.00 |
| Jun 30, 2024 | 119,331.00 |
| Mar 31, 2024 | 98,661.00 |
| Dec 31, 2023 | 52,463.00 |
| Sep 30, 2023 | 54,006.00 |
| Jun 30, 2023 | 53,871.00 |
| Mar 31, 2023 | 45,542.00 |
| Dec 31, 2022 | 32,219.00 |
| Sep 30, 2022 | 32,400.00 |
| Jun 30, 2022 | 31,881.00 |
| Mar 31, 2022 | 31,662.00 |
| Dec 31, 2021 | 30,639.00 |
| Sep 30, 2021 | 31,063.00 |
| Jun 30, 2021 | 30,813.00 |